Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer

被引:5
|
作者
Reinert, Tomas [1 ]
Barrios, Carlos H. [2 ]
机构
[1] Inst Canc Res, Sistema Saude Mae Deus, Porto Alegre, RS, Brazil
[2] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil
关键词
AROMATASE INHIBITORS; ANASTROZOLE; FULVESTRANT; COMBINATION;
D O I
10.1200/JCO.2015.66.0803
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1959 / +
页数:3
相关论文
共 50 条
  • [1] Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply
    Ellis, Matthew J.
    Robertson, John F. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1960 - +
  • [2] A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy
    Mei-Yin C. Polley
    Maura N. Dickler
    Jason Sinnwell
    Kathleen Tenner
    Juan de la Haba
    Sibylle Loibl
    Matthew P. Goetz
    Jonas Bergh
    John Roberston
    Fergus Couch
    Matthew J. Ellis
    Miguel Martin
    Breast Cancer Research and Treatment, 2021, 189 : 15 - 23
  • [3] A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy
    Polley, Mei-Yin C.
    Dickler, Maura N.
    Sinnwell, Jason
    Tenner, Kathleen
    de la Haba, Juan
    Loibl, Sibylle
    Goetz, Matthew P.
    Bergh, Jonas
    Roberston, John
    Couch, Fergus
    Ellis, Matthew J.
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 15 - 23
  • [4] Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
    Sharvina Ziyeh
    Lauren Wong
    Reva K. Basho
    Current Oncology Reports, 2023, 25 : 689 - 698
  • [5] Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
    Ziyeh, Sharvina
    Wong, Lauren
    Basho, Reva K.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (07) : 689 - 698
  • [6] Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma
    Gluck, S
    CANCER, 2002, 95 (11) : 2442 - 2443
  • [7] Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer
    Beck, J. Thaddeus
    ONCOTARGETS AND THERAPY, 2015, 8 : 3629 - 3638
  • [8] First-line ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis
    Tripathy, D.
    Hortobagyi, G.
    Chan, A.
    Im, S-A
    Chia, S.
    Yardley, D.
    Esteva, F. J.
    Hurvitz, S.
    Kong, O.
    Bao, W.
    Lorenc, K. Rodriguez
    Diaz-Padilla, I.
    Slamon, D. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer
    Tevaarwerk, Amye J.
    Wisinski, Kari B.
    O'Regan, Ruth M.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1148 - +
  • [10] Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
    Johnston, Stephen R. D.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (10):